The North American Intrauterine Contraceptive Devices market is Estimated to Grow aAround $789.8 million by 2019 - Report by MicroMarket Monitor

Share Article

The major drivers behind the growing intrauterine contraceptive devices market in North America include increasing rate of unplanned pregnancies, effective contraceptive method,and less side effects. http://www.micromarketmonitor.com/market/north-america-intrauterine-contraceptive-devices-9914049840.html

MicroMarket Monitor

MicroMarket Monitor

Key Players in the North American Intrauterine Contraceptive Devices are Bayer Health Care AG (A subsidiary of BAYER AG) (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis Plc. (Ireland), and medicines360 (Ireland).

The North American Intrauterine Contraceptive Devices report defines and segments the concerned market in North America with analysis and forecast of revenue. This market is estimated to grow around $789.8 million by 2019, at a developing CAGR of 0.3% from 2013 to 2018.

Browse through the TOC of the North American Intrauterine Contraceptive Devices market, to get an idea of the in-depth analysis provided. This also provides a glimpse of the market segmentation, and is supported by various tables and figures.

http://www.micromarketmonitor.com/market/north-america-intrauterine-contraceptive-devices-9914049840.html

Intrauterine device (IUCD) is a small contraceptive device that is inserted into the uterus to prevent pregnancy. The IUCDs are available in two types: the copper and hormonal IUCD. The hormonal IUCD contains progesterone, which is a synthetic version of the naturally occurring hormone progesterone. Both these types are very effective methods of contraception and can stay in place for an average of at least five years.

The major drivers behind the growing intrauterine contraceptive devices market in North America include increasing rate of unplanned pregnancies, effective contraceptive method,and less side effects as compared to other contraceptive methods.

In the U.S, 82.0% of the adolescent pregnancies are unplanned, accounting for one-fifth of all unintended pregnancies. The users, especially adolescents trust the intrauterine devices as it is extremely reliable and effective. As a result, long-acting reversible contraception (LARC) methods, such as intrauterine contraceptive devices are adopted on a large scale.

Speak to Analyst @http://www.micromarketmonitor.com/contact/9914049840-speak_to_analyst.html

The U.S. contribution to the intrauterine contraceptive devices market in North America is 93%, as of 2014.In the U.S, under the Affordable Care Act (ACA), birth control and some other preventive services are offered without co-payments or deductibles.

Also, many private firms are focusing on reducing unintended pregnancies and abortion related expenses; besides, the government also provides grants for IUCD products in order to encourage the usage of intrauterine contraceptive devices.

IUCD is safe and more effective than other contraceptives, such as oral contraceptives, as the other contraceptives have several side effects, such as dizziness, headache, light headedness, stomach upset, bloating, or nausea.

Early buyers will receive 10% customization on this report.
http://www.micromarketmonitor.com/contact/9914049840-request_for_customization.html

This market is segmented and forecast on the basis of different type and products. The marketed products in the purview of this report are: Mirena, Skyla, Paragard, Essure and pipeline product Livosert. The market is further segmented and forecast on the basis of major countries, such as the U.S., and Canada.

This report also includes the market share, value chain analyses, usage percentage and sales of different products, market metrics such as drivers, restraints and also the upcoming opportunities in the market. In addition, it presents a competitive landscape and company profiles of the key players in the market.

Related Reports :

Global Brachytherapy Market
The Global Brachytherapy Market, mainly driven by increasing ageing population with higher risk of chronic diseases and increasing procedures through minimal invasive surgery was pegged at $215 million in 2013 and expected to be $245 million by 2018. Brachytherapy involves the implantation of radioactivity within the body to ablate or kill cancer or tumour cells within or in close proximity to the target area in the body.

http://www.micromarketmonitor.com/market-report/global-brachytherapy-reports-4531094301.html

About MicroMarket Monitor :

MicroMarket Monitor identifies and attends to various unmet needs of different industrial verticals, which include value chain impact analysis. The company publishes about 12000 Market Research Reports on various Micro Markets across the world. The graphical nature and multidimensional analysis of these reports provide advanced Business Intelligence Tools to the clients in that particular target market.

Contact:
Mr. Chandrasekhar K.
5601 Bridge Street
Suite 300
Fort Worth, TX 76112
Tel: +1-888-502-0539
Email: sales(at)micromarketmonitor(dot)com
Connect with us on LinkedIn at http://www.linkedin.com/company/micromarketmonitor.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Mr. Chandrasekhar K.
@mmarketmonitor
Follow >
Micro Market Monitor
Like >
Follow us on
Visit website